Physician profile
Daniel Austin
NPI 1407274699
$3,853.84
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,064 · 2020: $209 · 2021: $1,030 · 2022: $20.12 · 2024: $531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $506 · Food and Beverage: $25.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $505.51 |
| Food and Beverage | $25.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $505.51 | 2024 | |
| Novo Nordisk INC | $480.18 | 2019-2021 | |
| Glaxosmithkline, LLC. | $395.44 | 2019-2021 | |
| Abbvie INC. | $354.25 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $312.41 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $243.52 | 2019-2021 | |
| Amgen INC. | $203.51 | 2019-2021 | |
| Lilly USA, LLC | $181.40 | 2019-2021 | |
| Pfizer INC. | $175.10 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $143.18 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $131.36 | 2019-2021 | |
| Astellas Pharma US INC | $105.04 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $102.74 | 2021 | |
| Amarin Pharma, INC. | $99.47 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.78 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $59.51 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.13 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.76 | 2019 | |
| Urovant Sciences INC | $42.35 | 2021 | |
| Nestle Healthcare Nutrition INC. | $38.98 | 2021 | |
| Novartis Pharmaceuticals Corporation | $27.52 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $27.05 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.98 | 2019 | |
| Acorda Therapeutics, INC | $15.67 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Austin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.